Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 5.38%
As of Thursday, August 13, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Commentary & Analysis
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 11.21%
As of Thursday, August 13, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 11.21%, which has investors questioning if this is right time to sell.Tudor Pop
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Down 5.53%
As of Monday, August 10, Polaryx Therapeutics, Inc.’s PLYX share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 5.21%
As of Friday, July 24, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 5.21%, which has investors questioning if this is right time to sell.Michael Rose
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Down 7.00%
As of Friday, July 10, Polaryx Therapeutics, Inc.’s PLYX share price has dipped by 7.00%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $123.1 | $587.7 | 23% |
|
| Shares Out (Mil) | 47.2 | 44.5 | 46% |
|
| Institutional Ownership | 13.2% | 84.6% | 8% |
|
| Float (Mil) | 4.3 | 46.8 | 11% |
|
| Beta | na | 0.69 | na |
|
| Avg Daily Volume (000s) | 96 | 361 | 34% |
|
| Price Change (52-week) |
na | 66.7% | na |
|
| Growth | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $276 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 32% |
|
| EPS (TTM) | ($0.140) | ($0.700) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $115 | $309 | 23% |
|
| Valuation | PLYX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 52.00 | 2.89 | 99% |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (163.1%) | (22.5%) | 3% |
|
| ROE | (192.2%) | (19.8%) | 4% |
|
| Liabilities to Assets | 29.0% | 32.4% | 20% |
|
| F-Score | 1 | 3 | 1% |
|
Polaryx Therapeutics, Inc. did not pass any screens on 8/14/2026.
